Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 29;9:969096. doi: 10.3389/fcvm.2022.969096

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Lobov, Boyarskaya, Kachanova, Gromova, Shishkova, Zainullina, Pishchugin, Filippov, Uspensky and Malashicheva.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Comparison of proteomics profiles of human valve interstitial cells (VICs) cultured for 10 days in osteogenic medium (OM), OM supplemented with DMSO (DMSO), OM supplemented with 100 nM of crenigacestat (LY3039478) dissolved in DMSO (Crenigacestat). (A) Venn diagram representing proteins unique for biological groups compared by shotgun proteomics. (B) Partial least-squares discriminant analysis. (C) Volcano plot representing differentially expressed proteins (protein names were converted to gene symbols) of VICs cultured with OM supplemented with crenigacestat against VICs cultured with OM and OM supplemented with DMSO. Log2Fold Change, level of change in expression; -Log10P, negative logarithm of the p-value. Dotted lines cut off transcripts with p-value < 0.05 and Log2Fold Change > |1|. (D) Results of Gene Ontology term enrichment analysis of proteins downregulated in VICs by crenigacestat treatment.

HHS Vulnerability Disclosure